| Symbol | JWCTF |
|---|---|
| Name | JW CAYMAN THERAPEUTICS CO LTD. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | |
| Telephone | — |
| Fax | — |
| — | |
| Website | https://www.jwtherapeutics.com/ |
| Incorporation | KY |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | NOT AVAILABLE |
| Reporting Status | International Reporting: Hong Kong Stock Exchange |
| CIK | — |
| Description | JW (Cayman) Therapeutics Co. Ltd (the "Company") is a global leading clinical stage cell therapy platform company. The Companys vision is to develop best-in-class and/or first-in-class cell therapies for the China market to transform the treatment of cancer for Chinese patients. Since the establishment of JW Shanghai in 2016 , it has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Additional info from OTC: |
No news found.